Sylvester Comprehensive Cancer Center

E-mail a Friend

Joseph D. Rosenblatt, M.D.

General Information

Joseph D. Rosenblatt, M.D.

Languages

  • English

Certifications

  • American Board of Internal Medicine
  • American Board of Internal Med-Medical Oncology

CV

Specialties

  • Hematology/Oncology - Internal Medicine
  • Internal Medicine

Roles

  • Professor of Medicine, Chief of Hematology- Oncology, William J. Harrington Chair in Hematology

Clinical Interests

Dr. Rosenblatt's clinical interests include hematologic malignancies, Lymphoma, certain  Leukemia's, and Multiple Myeloma.

Research Interests

In the past 20 years, Dr. Rosenblatt's work focused on human retroviruses, immune therapies for cancer and human gene therapy. Current work is directed to development of novel immune therapy and gene therapy strategies for breast and other cancers. The lab investigates the potential role of recruitment of immune effector cells that elaborate constitutive and inflammatory chemokines on the development of an anti-tumor response and the role of chemokines delivered alone or in combination with expression of the costimulatory ligands CD80 (B7.1) or CD40L. Several delivery strategies have been investigated, including the use of use of Herpes Simplex virus amplicon vectors in several murine tumor models. The Herpes Simplex amplicons are also being tested for efficacy in augmenting the immunogenicity of malignant cells. Novel methods of immune effector molecule delivery, which involve delivery by antibodies of a costimulatory molecule, anti-angiogenic peptide or a chemokine are also under investigation. Antibody fusion proteins targeting the human breast cancer her2/neu antigen, linked to the extracellular domains of T-cell costimulatory ligands and /or chemokines have been synthesized and are being tested for their in vitro ability to bind to cognate antigenic targets and to deliver a local costimulatory signal or chemotaxis signal. A novel therapeutic, that fuses the anti-angiogenic peptide endostatin to anti-her2/neu antibody, shows excellent efficacy in preclinical models. Currently, Dr. Rosenblatt is using a novel B-cell deficient mouse model to test antibody fusion protein targeting to xenogeneic (e.g. CEA, her2/neu) antigens, while preserving T-cell immune effector functions. The B cell deficient model has also demonstrated enhanced TH1 T cell responses to tumor compared to those seen in the immunocompetent mouse.

Awards

Outstanding Cancer Researcher Award
Champion of Medicine award
Iron Arrow Society
America’s Top Doctors for Cancer
Best Doctors in America
Emanuel G. Rosenblatt Award
Who’s Who in Medical Education
Award for Scientific Achievement
Who’s Who in Medical Education
Best Doctors in America
Best Doctors in America
Davey Memorial Award
Davey Memorial Award for Outstanding Cancer Research
Presidential Award, Society of Biological Therapy
Janssen Pharmaceutica Research
Presidential Award
Research Award
Who's Who in America
Fellow
Shannon Award
Fullbright Scholarship
Leukemia Research Foundation Award
Cancer Research Award
University-Wide Task Force
Fellow
Cancer Research Award
President's Undergraduate Fellowship Award

Education

1986 Fellowship
UCLA - University of California, School of Medicine
1983 Residency
UCLA - University of California, School of Medicine
1980 M.D.
UCLA - University of California, School of Medicine
1976 B.S.
University of California

Publications

  • Rosenblatt, J.D; Podack, E.R.; Barber, G.N.; Ochoa, A, Editors. Advances in Tumor Immunology and Immunotherapy, Springer; 2014,IX, 371.
  • Talebi, Tony; Rosenblatt, JD. Hematology and Transfusion Medicine Board Review Made Simple: Case Series which cover topics for the USMLE, Internal Medicine & Hematology Boards. Onlineboardreview.net. 2011 July.
  • Lossos, I; Rosenblatt, JD. Rituximab for Treatment of Chemo-Immunotherapy Naïve Marginal Zone Lymphoma GLAL-2007-0234. Leukemia and Lymphoma. 2007 Aug; 48(8): 1630-1632.
  • Zhang, Y; Nechushtan, H; Chan, Andrew; Podack, E; Levy, R; Rosenblatt, J. Immune effects of B cell depletion on the T cell response: Analysis in the human CD20 transgenic mouse model, Rituximab-mediated Molecular Signaling and Interaction with Chemotherapeutic Drugs, 2007
  • Raez LE, Rosenblatt JD, Podack ER. Present and future of lung cancer vaccines. Expert Opin Emerg Drugs. 2006 Sep;11(3):445-59.
  • Calfa CI, Rosenblatt JD, Cho H, Webster K, Shin S. Antibodies and antibody-fusion proteins as anti-angiogenic, anti-tumor agents. Update on Cancer Therapeutics. 2006 Jun;1(2):159-73.
  • Calfa, C; Rosenblatt, J; Cho, H; Webster, K; Shin, S. Antibodies and Antibody-fusion Proteins as Anti-angiogenic, Anti-tumor Agents. Cancer Chemotherapy & Biological Response Modifiers Annual 23. 1(2) 159-173. 2006.
  • Santos ES, Rosenblatt JD, Goodman M. Role of farnesyltransferase inhibitors in hematologic malignancies. Expert Rev Anticancer Therapy, Vol. 4(5) 2004, 843-856.
  • Lancet JE, Rosenblatt JD, Karp JE. Farnesyltransferase Inhibitors in Leukemia. Annals of Hematology, Acute Leukemias 1X, Basic Research, Experimental Approaches and Novel Therapies. Haematology and Blood Transfusion Hämatologie und Bluttransfusion Volume 41, 2003, pp 90-96
  • Rosenblatt JD, Harrington WJ. Leukemia and Myelopathy: the persistent mystery of pathogenesis by HTLV-I/II. Cancer Investigation. 2003 Apr; 21(2): 323-4.
  • Santos ES, Rosenblatt JD. Combining Interleukin-2 with Monoclonal Antibody Therapy for the Treatment of Non-Hodgkins Lymphomas. Immune-Enhancing Cytokines, 2003, Vol. 5, No. 2.
  • Andela VB, Pirri M, Schwarz EM, Puzas EJ, O’Keefe JR, Rosenblatt JD, Rosier RN. The mevalonate synthesis pathway as a therapeutic target in cancer. Clin Orthop Relat Res 2003 (415 Suppl):S59-66.
  • Lancet JE, Rosenblatt JD, Karp JE. Farnesyltransferase Inhibitors and Myeloid Malignancies: Phase I Evidence of ZARNESTRA activity in high-risk leukemias. Seminars in Hematology, Vol 39, No 3, Suppl 2, 2002, 31-35.
  • Assessing the future landscape in myleloid malignancies: Evolving insights on farnesyltransferase inhibitors. J. Rosenblatt, Editor. Seminars in Hematology. 2002.
  • Karp JE, Lancet JE, Wright J, Rosenblatt JD. Farnesyltransferase inhibition in leukemias: correlative clinical-laboratory trials with Zarnestra (R11577). Blood-Immunity-Cancer , Vol 7, No. 1 67-72, 2002
  • Morgensztern D, Wolin M, Rosenblatt, JD. Interleukin-2 and Rituximab in Lymphoma: Rationale and Current Trials. Biological Therapy of Lymphoma, 2002, Vol. 5, No. 4, pp 12-15.
  • Rosenblatt JD, Shin Seung-Uon, Nechustan H, Yi KH. Potential role of chemokines in immune therapy of cancer. Israeli Medical Assoc Journal, 2002, 4(11):1054-1059.
  • Rubin P, Williams, Okunieff P, Rosenblatt JD, Sitzmann J. Statement of the Clinical Oncologic Problem. In: Clinical Oncology, 8th Edition, Ed: Phillip Rubin. WB Saunders Co, Philadelphia, 2001, 1-31.
  • Collichio F, Griggs, J, Rosenblatt JD, Gene Therapy for Cancer. In: Clinical Oncology, 8th Edition, Ed: Philip Rubin. WB Saunders Co, Philadelphia, 2001, 160-167.
  • Tolba K, Federoff HJ, Rosenblatt JD. Gene Therapy for Cancer. In: Clinical Oncology, 8th Edition, Ed: Philip Rubin. WB Saunders Co, Philadelphia, 2001, 168-184.
  • Maurer C, Harrington WJ, Gill P, Kampe CE, Rosenblatt JD. Adult T-cell Leukemia/Lymphoma. In: Cancer Treatment, 5th Edition, Chapter 96, Ed: Haskell CM, WB Saunders Co, Philadelphia, PA., 2001, 1474-1486.
  • Khorana A, Rosenblatt J, Young F. Immunopathogenesis of HIV and HTLV-1 Infection: Mechanisms for Lymphomagenesis. In: Cancer Treatment and Research Series; HIV-Associated Malignancies. Ed: Joseph A. Sparano, M.D., Kluwer Academic Publishers, Norwell, MA., 2001, Chapter 2:19-74.
  • Iftikharuddin, JJ, Rosenblatt, JD. Type C oncoviruses-Human T-cell lymphotropic virus Types I and II. In: Principles and Practice of Infectious Diseases, 5th Edition, Volume 2. Eds: Mandell GL, Bennett, JE and Dolin, WB Saunders Co., Philadelphia, PA, 2000.
  • Mahmood, K, Tolba K, Federoff HJ, Rosenblatt JD. The role of HSV amplicon vectors in cancer gene therapy. In: Gene Therapy and Molecular Biology, Boulikas T (ed), 1999, 4:209-219.
  • Rimel BJ, Rosenblatt JD, Planelles V. HTLV-II. Encyclopedia of Virology, Second Edition, Granoff A, Webster RG (eds), Academic Press, San Diego, CA, 1999.
  • Klimatcheva E, Rosenblatt JD, Planelles V. Lentiviral vectors and Gene Therapy. Frontiers in Bioscience, 1999, 4:D481-96.
  • Newman CL, Rosenblatt JD. Human T-cell lymphotropic viruses. Chapter in Human Tumor Viruses. American Society of Microbiology Pres, McCance D., Editor, 1998, pp. 331-357. Ifthikharuddin JJ, Rosenblatt JD. Introduction-Type C oncoviruses including human T-cell lymphotropic virus types I and II. In: Principles of Infectious Diseases, 5th Edition. GL Mandell, JE Bennett, R Doplin (eds). Churchill Livingstone international, New York, NY 1998.
  • Newman CL, Rosenblatt JD. Human T-cell lymphotropic viruses. Chapter in Human Tumor Viruses. American Society of Microbiology Pres, McCance D., Editor, 1998, pp. 331-357. Ifthikharuddin JJ, Rosenblatt JD. Introduction-Type C oncoviruses including human T-cell lymphotropic virus types I and II. In: Principles of Infectious Diseases, 5th Edition. GL Mandell, JE Bennett, R Doplin (eds). Churchill Livingstone international, New York, NY 1998.
  • Ferreira OC Jr, Planelles V, Rosenblatt JD. Human T-Cell leukemia viruses: epidemiology, biology, and pathogenesis. Blood Reviews. 1997 Jun;11(2):91-104
  • Rosenblatt JD, Miles S, Gasson JC, Prager D. Transactivation of cellular genes by human retroviruses. In Transacting Functions of Human Retroviruses, Clinical Topics in Microbiology and Immunology. Chen ISY, Koprowski H, Srinivasan A, Vogt PK, eds. Springer Verlag, New York 1995.
  • Rosenblatt JD, Black AC: Human T-cell leukemia viruses: HTLV-2. In Encyclopedia of Virology, Webster RG (ed). Saunders Scientific Publications, W.B. Saunders Co., London, 1994, pp 686-695.
  • Rosenblatt, JD. A Human Non-HIV retroviral infections; Editorial Comment in Infections in Medicine, 1994, 11:547
  • Kampe CE, Harrington WB, Gill P, Black AC Saunders, Rosenblatt JD. Adult T-cell leukemia/lymphoma, Cancer Treatment, 4th ed., Saunders Haskell, C. Editor, 1994, Chapter 95.
  • Rosenblatt, JD. Human T-lymphotropic virus types I and II. Western Journal of Medicine, 1993, 158:379-384.
  • Black AC, Rosenblatt JD. Human T-cell leukemia virus infections. In: Infectious Diseases: A Treatise of Infectious Processes, fifth edition, JB Lippincott 1993.
  • Rosenblatt JD, Danon Y, Black AC: A decade with HTLV-I and HTLV-II: Lessons in viral leukemogenesis. Leukemia, 1992, 6:18-23
  • Rosenblatt JD: Human Retrovirology: HTLV. In Cancer Cells, Blattner W (ed). Cold Spring Harbor Publications, Cold Spring Harbor, NY, 1991, 155-157.
  • Chen ISY, Rosenblatt JD: Human T-Cell Leukemia Virus Type II, in The Human Retroviruses, Gallo R, Jay G, eds. Academic Press, Inc., New York, 1991, 21-33.
  • Black AC, Nimer SD, Chen ISY, Rosenblatt JD: The effects of Tax and Rex proteins of HTLV-I/-II on viral and cellular gene regulation. UCLA Symposium on Human Retroviruses, Groopman J, Chen ISY, Essex M, Weiss R, Eds. Alan R. Liss, New York, 1991.
  • Rosenblatt JD, Wachsman W, Chen ISY: Retroviruses and Leukemia: Recent Developments, in Leukemia: Recent Progress, Future Advances, UCLA Hyland Colloquium, Gale RP, Rai K, eds. Alan R. Liss, New York, 1991.
  • Cann AJ, Rosenblatt JD, Wachsman W, Chen ISY: Molecular biology and pathogenesis of HTLV-II. In Retrovirus Biology: An Emerging Role in Human Diseases, Gallo RC, Wong-Staal F, eds. Marcel Dekker, New York, 1991.
  • Panoskaltsis N, Rosenblatt JD. A Cell Therapy: Stem Cell Transplantation, Gene Therapy, and Cellular Immunotherapy: by George Mortsyn and William Sheridean. Editorial (Book Review) in Bulletin of the New York Academy of Medicine: A Journal of Urban Health, 1996, 922-926.
  • Black AC, Rosenblatt JD, Chen ISY: Viral Trans-activating Genes. In Genes and Cancer, Sikora K, Carney D (eds). John Wiley & Sons, West Sussex England, 1990, 137-150.
  • Rosenblatt JD, Zack JA, Chen ISY, Lee H: Recent advances in detection of HTLV-I and HTLV-II infection. J Nat Immun Cell Growth Regul, 1990, 9:143-149.
  • Chen ISY, Cann AJ, Lugo JP, Rosenblatt JD: Models for Mechanisms of Transformation by the Human T-cell Leukemia Viruses. In Retroviruses and Disease, Pullman ME, Hanafusa H, Pinter A (eds). Academic Press, Inc., New York, 1989, 113-125
  • Rosenblatt JD, Chen ISY, Golde DW: HTLV-II and human lymphoproliferative disorders. In Clinics in Laboratory Medicine, Yeager E, ed. Saunders, Philadelphia PA, Vol. 8, 1988,85-95.
  • Rosenblatt JD, Chen ISY, Wachsman W: Infection with HTLV-I and HTLV-II: Evolving Concepts. Semin Hematol, 1988, 25:230-246.
  • Aboud M, Wachsman W, Rosenblatt JD, Cann AJ, Golde DW, Gaynor RB, Slamon DJ, Chen ISY: Biology and Leukemogenicity of human T-cell leukemia viruses. In Viruses and Human Cancer, UCLA Symposia on Molecular and Cellular Biology, Park City, UT, Vol 43, Gallo RC, Haseltine W, Klein G, zur Hausen H, eds. Alan R. Liss, New York, 1987, pp 109-129.
  • Cann AJ, Rosenblatt JD, Shah NP, Williams J, Wachsman W, Chen ISY: Expression of the human T-cell leukemia virus x gene in vitro. In Viruses and Human Cancer, UCLA Symposia on Molecular and Cellular Biology, Park City UT, Vol 43, Gallo RC, Haseltine W, Klein G, zur Hausen H, eds. Alan R. Liss, New York, 1987, 221-235.
  • Naeim F, Kemani-Arab V, Hoon D, Gatti D, Rosenblatt J, Concannon P: Immortalization of T-lymphocytes derived from Patients with Hairy Cell Leukemia of B-cell type. In Recent Advances in Leukemia and Lymphoma, Gale RP, Golde DW, eds. Alan R. Liss, New York, Vol 61, 1987
  • Rosenblatt JD, Wachsman W, Chen ISY: Retroviruses and Leukemia: Recent Developments. In Chronic Lymphocytic Leukemia: Recent Progress and Future Directions, UCLA Hyland Colloquium, Gale RP, Rai K, eds. Alan R. Liss, New York, 1987, 11-28.
  • Rosenblatt JD, Cann AJ, Golde DW, Chen ISY: Structure and Function of the Human T-cell Leukemia Virus II genome. In Cancer Reviews, Vol. 1, Hinuma Y (ed.). Munksgaard, Copenhagen Denmark, 1986, 115-135.
  • Chen ISY, Wachsman W. Rosenblatt JD, Cann AJ: The role of x the gene in HTLV-associated Malignancy. Cancer Surveys, 5, London England, 1986.
  • Rosenblatt J, Wachsman W, Shimotohno K, Slamon D, Chen ISY: The comparative molecular biology of HTLV-I and HTLV-II. In Retroviruses in Human Lymphoma/Leukemia, Miwa M, et al. (eds). Japan Scientific Society Press,Tokyo VnY Science Press, Utrecht, 1985, 177-185.
  • Rosenblatt JD, Wachsman W, Shimotohno K, Slamon D, Chen IS. The comparative molecular biology of HTLV-I and HTLV-II. Princess Takamatsu Symp. 1984;15:177-85. Review

Biography

Joseph D. Rosenblatt, M.D., is a Professor of Medicine, and the William J. Harrington Chair in Hematology and Chief of Hematology/Oncology in the Department of Medicine. He holds a graduate cross appointment in the Department of Microbiology and Immunology at UM. Dr. Rosenblatt is also a member of the Tumor Immunology Program. In the past 20 years, Dr. Rosenblatt has published over 100 journal articles and chapters in the areas of human retroviruses, immune therapies for cancer, and human gene therapy. Dr. Rosenblatt's work has general relevance to breast cancer and he has held major breast cancer grant funding in the past. Prior to his move to Miami, Dr. Rosenblatt served as Chief of the Hematology-Oncology Unit, and had a secondary appointment within the Department of Microbiology and Immunology at the University of Rochester from 1995-2001. Prior to 1995, Dr. Rosenblatt had been a member of the faculty in Hematology Oncology (Associate Professor) and was elected an Associate Member of the Molecular Biology Institute at UCLA, California. Dr Rosenblatt joined University of Miami in 2001, bringing extensive administrative and research experience. He has had continuous NIH and other extramural funding for retroviral, gene therapy and immunotherapy related research since 1986 and has been a standing member of the NCI Experimental Therapeutics II (ET-2) and currently the Clinical Immunology and Immunotherapy II (C-II) study sections. As a Clinician Scientist, his mentorship is of particular importance as SCCC scientist seek to enhance cross talk between our post-PhD and post-MD Fellows in this Breast Cancer Translational Research. His research relevant to Breast Cancer includes the synthesis and testing of novel antibody—fusion proteins which target the HER2 breast cancer antigen, and can inhibit angiogenesis or augment immune response to breast cancer.

E-mail a Friend